L
Leslie M. Shaw
Researcher at University of Pennsylvania
Publications - 664
Citations - 56129
Leslie M. Shaw is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Alzheimer's disease & Dementia. The author has an hindex of 114, co-authored 616 publications receiving 48009 citations. Previous affiliations of Leslie M. Shaw include Memorial Hospital of South Bend & Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R. Jack,David S. Knopman,William J. Jagust,Leslie M. Shaw,Paul S. Aisen,Michael W. Weiner,Ronald C. Petersen,John Q. Trojanowski +7 more
TL;DR: This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity.
Journal ArticleDOI
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Clifford R. Jack,David S. Knopman,William J. Jagust,Ronald C. Petersen,Michael W. Weiner,Paul S. Aisen,Leslie M. Shaw,Prashanthi Vemuri,Heather J. Wiste,Stephen D. Weigand,Timothy G. Lesnick,Vernon S. Pankratz,Michael C. Donohue,John Q. Trojanowski +13 more
TL;DR: In this article, a model of the major biomarkers of Alzheimer's disease (AD) was proposed and the authors described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms.
Journal ArticleDOI
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw,Hugo Vanderstichele,Malgorzata Knapik-Czajka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam J. Simon,Piotr Lewczuk,Robert A. Dean,Eric Siemers,William Z. Potter,Virginia M.-Y. Lee,John Q. Trojanowski +14 more
TL;DR: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Journal ArticleDOI
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
Ronald C. Petersen,Paul S. Aisen,Laurel A. Beckett,Michael C. Donohue,Anthony Gamst,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski,Michael W. Weiner +11 more
TL;DR: The Alzheimer's Disease Neuroimaging Initiative has successfully recruited cohorts of cognitively normal subjects, subjects with mild cognitive impairment (MCI), and subjects with Alzheimer disease with anticipated baseline characteristics and the CSF measures heralded progression of clinical measures over 12 months.
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Michael W. Weiner,Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Enchi Liu,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Mark E. Schmidt,Leslie M. Shaw,Judith Siuciak,Holly Soares,Arthur W. Toga,John Q. Trojanowski +19 more
TL;DR: The major accomplishments of ADNI have been the development of standardized methods for clinical tests, magnetic resonance imaging, positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting, and the improvement of clinical trial efficiency.